- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | GSK commits $800M to R&D, manufacturing hub, as Pennsylvania bonds deepen | ||
| Fr | Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger | ||
| Fr | FDA's Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data | ||
| Fr | Quince relaunches as IRuyla, going all in on lung disease after Hail Mary merger | ||
| Fr | Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives | ||
| Fr | Fierce Pharma Asia-Novartis' $7.8B mRNA deal; Shionogi's $2B buy; ArriVent's phase 3 flop | ||
| Fr | Pharma's free lunches for clinicians bloat prescription bills: Cochrane review | ||
| Do | BMS fills out Zenbexus picture with post-approval PFS victory in multiple myeloma | ||
| Do | Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B | ||
| Do | Pfizer's Tukysa snags first-line approval in HER2+ breast cancer | ||
| Do | CSL Seqirus blasted for 'multiple and prolonged deficiencies' | ||
| Do | Argenx walks away from Vyvgart Sjögren's disease trial after futility flag | ||
| Do | Melissa explains it all in menopause team up with Bayer | ||
| Do | Theramex pays up to $250M for Asieris' novel cervical lesion treatment | ||
| Mi | Novartis' Rhapsido tackles 2 most common forms of chronic hives with swift FDA expansion | ||
| Mi | Sanofi drafts NY Knicks star Karl-Anthony Towns for COVID, Nuvaxovid awareness push | ||
| Mi | Halozyme stymies subcutaneous Keytruda launch in select European countries as Merck vows to fight patent claims | ||
| Mi | How drugmakers are tapping into the GLP-1 frenzy's unprecedented 'consumer overlay' | ||
| Mi | New API Innovation Center index spotlights supply chain stress points | ||
| Mi | Catalent wins access to Iro and launches next-gen development platform | ||
| Mi | Scaling psychedelics comes with uncertainty 'baked into the sauce' | ||
| Mi | Rising Stars: How VML Health's Molly Kanofsky turns 'an idea on a page' into real-world impact | ||
| Mi | ViiV girds data package for Cabenuva in competitive HIV treatment market | ||
| Di | AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy | ||
| Di | BD commits $19B amid US onshoring push, with $3B earmarked for manufacturing growth |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.